57 related articles for article (PubMed ID: 36031559)
1. Assessing Outlier Probabilities in Transcriptomics Data When Evaluating a Classifier.
Kircher M; Säurich J; Selle M; Jung K
Genes (Basel); 2023 Feb; 14(2):. PubMed ID: 36833313
[TBL] [Abstract][Full Text] [Related]
2. Genomic biomarkers to guide precision radiotherapy in prostate cancer.
Sutera P; Deek MP; Van der Eecken K; Wyatt AW; Kishan AU; Molitoris JK; Ferris MJ; Siddiqui MM; Rana Z; Mishra MV; Kwok Y; Davicioni E; Spratt DE; Ost P; Feng FY; Tran PT
Prostate; 2022 Aug; 82 Suppl 1(Suppl 1):S73-S85. PubMed ID: 35657158
[TBL] [Abstract][Full Text] [Related]
3. PAM50 and Beyond: When Will Tissue Transcriptomics Guide Clinical Decision-making?
Haywood SC; Gupta S; Heemers HV
Eur Urol Focus; 2022 Jul; 8(4):916-918. PubMed ID: 36031559
[TBL] [Abstract][Full Text] [Related]
4. A comparative study of PCS and PAM50 prostate cancer classification schemes.
Yoon J; Kim M; Posadas EM; Freedland SJ; Liu Y; Davicioni E; Den RB; Trock BJ; Karnes RJ; Klein EA; Freeman MR; You S
Prostate Cancer Prostatic Dis; 2021 Sep; 24(3):733-742. PubMed ID: 33531653
[TBL] [Abstract][Full Text] [Related]
5. Translating a Prognostic DNA Genomic Classifier into the Clinic: Retrospective Validation in 563 Localized Prostate Tumors.
Lalonde E; Alkallas R; Chua MLK; Fraser M; Haider S; Meng A; Zheng J; Yao CQ; Picard V; Orain M; Hovington H; Murgic J; Berlin A; Lacombe L; Bergeron A; Fradet Y; Têtu B; Lindberg J; Egevad L; Grönberg H; Ross-Adams H; Lamb AD; Halim S; Dunning MJ; Neal DE; Pintilie M; van der Kwast T; Bristow RG; Boutros PC
Eur Urol; 2017 Jul; 72(1):22-31. PubMed ID: 27815082
[TBL] [Abstract][Full Text] [Related]
6. Quantitative and Qualitative Analysis of Blood-based Liquid Biopsies to Inform Clinical Decision-making in Prostate Cancer.
Casanova-Salas I; Athie A; Boutros PC; Del Re M; Miyamoto DT; Pienta KJ; Posadas EM; Sowalsky AG; Stenzl A; Wyatt AW; Mateo J
Eur Urol; 2021 Jun; 79(6):762-771. PubMed ID: 33422353
[TBL] [Abstract][Full Text] [Related]
7. Genomic Markers in Prostate Cancer Decision Making.
Cucchiara V; Cooperberg MR; Dall'Era M; Lin DW; Montorsi F; Schalken JA; Evans CP
Eur Urol; 2018 Apr; 73(4):572-582. PubMed ID: 29129398
[TBL] [Abstract][Full Text] [Related]
8. Genomic Tests Should be Used to Help Guide Treatment of Prostate Cancer: Yes.
Palapattu GS
J Urol; 2017 Aug; 198(2):265-266. PubMed ID: 28629664
[No Abstract] [Full Text] [Related]
9. Therapeutic Implications for Intrinsic Phenotype Classification of Metastatic Castration-Resistant Prostate Cancer.
Coleman IM; DeSarkar N; Morrissey C; Xin L; Roudier MP; Sayar E; Li D; Corey E; Haffner MC; Nelson PS
Clin Cancer Res; 2022 Jul; 28(14):3127-3140. PubMed ID: 35552660
[TBL] [Abstract][Full Text] [Related]
10. Prognosis Associated With Luminal and Basal Subtypes of Metastatic Prostate Cancer.
Aggarwal R; Rydzewski NR; Zhang L; Foye A; Kim W; Helzer KT; Bakhtiar H; Chang SL; Perry MD; Gleave M; Reiter RE; Huang J; Evans CP; Alumkal JJ; Lang JM; Yu M; Quigley DA; Sjöström M; Small EJ; Feng FY; Zhao SG
JAMA Oncol; 2021 Nov; 7(11):1644-1652. PubMed ID: 34554200
[TBL] [Abstract][Full Text] [Related]
11. Transcriptional profiling of primary prostate tumor in metastatic hormone-sensitive prostate cancer and association with clinical outcomes: correlative analysis of the E3805 CHAARTED trial.
Hamid AA; Huang HC; Wang V; Chen YH; Feng F; Den R; Attard G; Van Allen EM; Tran PT; Spratt DE; Dittamore R; Davicioni E; Liu G; DiPaola R; Carducci MA; Sweeney CJ
Ann Oncol; 2021 Sep; 32(9):1157-1166. PubMed ID: 34129855
[TBL] [Abstract][Full Text] [Related]
12. Diversity in Androgen Receptor Action Among Treatment-naïve Prostate Cancers Is Reflected in Treatment Response Predictions and Molecular Subtypes.
Ben-Salem S; Hu Q; Liu Y; Alshalalfa M; Zhao X; Wang I; Venkadakrishnan VB; Senapati D; Kumari S; Liu D; Sboner A; Barbieri CE; Feng F; Billaud JN; Davicioni E; Liu S; Heemers HV
Eur Urol Open Sci; 2020 Dec; 22():34-44. PubMed ID: 33299986
[TBL] [Abstract][Full Text] [Related]
13. Transcriptomic Heterogeneity of Androgen Receptor Activity Defines a
Spratt DE; Alshalalfa M; Fishbane N; Weiner AB; Mehra R; Mahal BA; Lehrer J; Liu Y; Zhao SG; Speers C; Morgan TM; Dicker AP; Freedland SJ; Karnes RJ; Weinmann S; Davicioni E; Ross AE; Den RB; Nguyen PL; Feng FY; Lotan TL; Chinnaiyan AM; Schaeffer EM
Clin Cancer Res; 2019 Nov; 25(22):6721-6730. PubMed ID: 31515456
[TBL] [Abstract][Full Text] [Related]
14. Development and Validation of a Prostate Cancer Genomic Signature that Predicts Early ADT Treatment Response Following Radical Prostatectomy.
Karnes RJ; Sharma V; Choeurng V; Ashab HA; Erho N; Alshalalfa M; Trock B; Ross A; Yousefi K; Tsai H; Zhao SG; Tosoian JJ; Haddad Z; Takhar M; Chang SL; Spratt DE; Abdollah F; Jenkins RB; Klein EA; Nguyen PL; Dicker AP; Den RB; Davicioni E; Feng FY; Lotan TL; Schaeffer EM
Clin Cancer Res; 2018 Aug; 24(16):3908-3916. PubMed ID: 29760221
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
